新诊断帕金森病运动进展临床与遗传预测因素的大规模识别:纵向队列研究与验证
该研究基于PPMI队列(312例帕金森病患者和117例健康对照)和LABS-PD验证队列(317例帕金森病患者),利用贝叶斯多变量预测推断平台构建模型集成,预测MDS-UPDRS第II和III部分总分年变化率。模型在PPMI中交叉验证R2为41%(95%CI 35-47),在LABS-PD中R2为9%(95%CI 4-16),并确认基线MDS-UPDRS运动评分较高、男性和年龄增加可预测更快的运动进展,还发现帕金森病特异性上位性交互作用;模拟试验显示将预测的进展率纳入治疗效应模型可降低结局变异性,使所需样本量最多减少20%。
要点
- 基线MDS-UPDRS运动评分较高、男性、年龄增加与更快的运动进展相关。
- 将预测的进展率纳入治疗效应模型可使试验所需样本量最多减少20%。
核心结论
- 模型集成确认了已建立的预测因素并识别了帕金森病运动进展的新预测因素。
- 通过机器学习方法改进现有预后模型应有益于试验设计、评估以及临床疾病监测和治疗。
研究设计与样本
- 研究应用贝叶斯多变量预测推断平台,使用PPMI研究(NCT01141023)中117例健康对照和312例帕金森病患者的遗传数据及基线分子和临床变量构建模型集成。
- 模型预测MDS-UPDRS第II和III部分合并评分的年变化率,并在LABS-PD独立临床队列(NCT00605163)的317例帕金森病患者中进行验证。
- 通过比较LABS-PD样本外队列中模拟的随机安慰剂对照试验(n=5000)量化模型对临床试验设计的潜在效用。
主要发现
- 模型集成在PPMI队列中表现强劲,五折交叉验证R2为41%(95%CI 35-47);在LABS-PD队列中性能显著但降低,R2为9%(95%CI 4-16)。
- PPMI数据识别的个体预测特征在LABS-PD队列中得到确认,包括基线MDS-UPDRS运动评分较高、男性和年龄增加,以及一种新的帕金森病特异性上位性交互作用,均提示更快的运动进展。
- 模拟(n=5000)显示将预测的运动进展率纳入最终治疗效应模型可降低研究结局变异性,使样本量最多减少20%即可检测到显著差异。
临床怎么用
- 基线MDS-UPDRS运动评分、性别、年龄和遗传变异可用于预测新诊断帕金森病患者的运动进展速度。
- 预测模型可用于优化临床试验设计,通过纳入预测的进展率降低样本量需求。
- 模型改进有望用于临床疾病监测和治疗评估。
局限性
- 模型在外部验证队列LABS-PD中的预测性能显著降低(R2 9% vs PPMI中41%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Better understanding and prediction of progression of Parkinson's disease could improve disease management and clinical trial design. We aimed to use longitudinal clinical, molecular, and genetic data to develop predictive models, compare potential biomarkers, and identify novel predictors for motor progression in Parkinson's disease. We also sought to assess the use of these models in the design of treatment trials in Parkinson's disease. METHODS: A Bayesian multivariate predictive inference platform was applied to data from the Parkinson's Progression Markers Initiative (PPMI) study (NCT01141023). We used genetic data and baseline molecular and clinical variables from patients with Parkinson's disease and healthy controls to construct an ensemble of models to predict the annual rate of change in combined scores from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II and III. We tested our overall explanatory power, as assessed by the coefficient of determination (R2), and replicated novel findings in an independent clinical cohort from the Longitudinal and Biomarker Study in Parkinson's disease (LABS-PD; NCT00605163). The potential utility of these models for clinical trial design was quantified by comparing simulated randomised placebo-controlled trials within the out-of-sample LABS-PD cohort. FINDINGS: 117 healthy controls and 312 patients with Parkinson's disease from the PPMI study were available for analysis, and 317 patients with Parkinson's disease from LABS-PD were available for validation. Our model ensemble showed strong performance within the PPMI cohort (five-fold cross-validated R2 41%, 95% CI 35-47) and significant-albeit reduced-performance in the LABS-PD cohort (R2 9%, 95% CI 4-16). Individual predictive features identified from PPMI data were confirmed in the LABS-PD cohort. These included significant replication of higher baseline MDS-UPDRS motor score, male sex, and increased age, as well as a novel Parkinson's disease-specific epistatic interaction, all indicative of faster motor progression. Genetic variation was the most useful predictive marker of motor progression (2·9%, 95% CI 1·5-4·3). CSF biomarkers at baseline showed a more modest (0·3%, 95% CI 0·1-0·5) but still significant effect on prediction of motor progression. The simulations (n=5000) showed that incorporating the predicted rates of motor progression (as assessed by the annual change in MDS-UPDRS score) into the final models of treatment effect reduced the variability in the study outcome, allowing significant differences to be detected at sample sizes up to 20% smaller than in naive trials. INTERPRETATION: Our model ensemble confirmed established and identified novel predictors of Parkinson's disease motor progression. Improvement of existing prognostic models through machine-learning approaches should benefit trial design and evaluation, as well as clinical disease monitoring and treatment. FUNDING: Michael J Fox Foundation for Parkinson's Research and National Institute of Neurological Disorders and Stroke.
引用
- Latourelle JC, Beste MT, Hadzi TC, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. Lancet Neurol. 2017. PMID: 28958801. doi:10.1016/S1474-4422(17)30328-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。